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Abstract
Background: Mutations in the presenilin (PSEN) genes are associated with early-onset familial
Alzheimer's disease (FAD). Biochemical characterizations and comparisons have revealed that
many PSEN mutations alter γ-secretase activity to promote accumulation of toxic Aβ42 peptides.
In this study, we compared the histopathologic and biochemical profiles of ten FAD cases
expressing independent PSEN mutations and determined the degradation patterns of amyloid-β
precursor protein (AβPP), Notch, N-cadherin and Erb-B4 by γ-secretase. In addition, the levels of
Aβ40/42 peptides were quantified by ELISA.
Results: We observed a wide variation in type, number and distribution of amyloid deposits and
neurofibrillary tangles. Four of the ten cases examined exhibited a substantial enrichment in the
relative proportions of Aβ40 over Aβ42. The AβPP N-terminal and C-terminal fragments and Tau
species, assessed by Western blots and scanning densitometry, also demonstrated a wide variation.
The Notch-1 intracellular domain was negligible by Western blotting in seven PSEN cases. There
was significant N-cadherin and Erb-B4 peptide heterogeneity among the different PSEN mutations.
Conclusion: These observations imply that missense mutations in PSEN genes can alter a range of
key γ-secretase activities to produce an array of subtly different biochemical, neuropathological and
clinical manifestations. Beyond the broad common features of dementia, plaques and tangles, the
various PSEN mutations resulted in a wide heterogeneity and complexity and differed from
sporadic AD.
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Background
Mutations in the presenilin-1 (PSEN1) and presenilin-2
(PSEN2) genes cause early-onset and aggressive forms of
familial Alzheimer's disease (FAD). In humans the PSEN1
and PSEN2 genes are localized on chromosome 14 and
chromosome 1, respectively, and encode for proteins with
65% amino acid sequence identity [1]. Presenilin-1 and
PSEN2, 467 and 448 amino acids long, respectively, have
nine transmembrane domains (TMD), two of which
(TMD6 and TMD7) contain catalytic Asp residues at posi-
tions 257 and 385 forming an active center required for
endoproteolysis [2,3]. More than 150 mutations in
PSEN1 and PSEN2 have been reported http://www.mol
gen.ua.ac.be/ADMutations). The presenilins are part of γ-
secretase, a heterotetrameric aspartyl membrane-bound
protease complex comprised of four interacting mole-
cules: PSEN, nicastrin, anterior pharynx defective 1
(Aph1) and presenilin enhancer 2 (Pen2) [4-6]. The bio-
chemical and functional characterization of γ-secretase in
recent years (reviewed in reference [7]) has permitted a
better understanding of the hydrolysis of hydrophobic
TMD and the important functional roles of their by-prod-
ucts. Gamma-secretase interacts with more than 25 differ-
ent substrates, thus potentially participating in a wide
range of cellular functions [8-11].
One of the numerous important substrates of the γ-secre-
tase is the amyloid-beta precursor protein (AβPP), a type-
1 membrane-bound molecule that is degraded by the
action of the β- and γ-secretases to yield the 40/42 amino
acid amyloid-β (Aβ) peptides. Gamma-secretase also
hydrolyzes the AβPP at the ε-site to generate the transcrip-
tion factor Aβ-intracellular domain (AICD) [12]. In AD,
Aβ peptides deposit in the brain parenchyma and in the
walls of the cerebral vasculature. The vast majority of FAD,
resulting from mutations in the AβPP and PSEN genes,
share the neuropathology observed in sporadic AD (SAD)
which typically includes amyloid plaques and cerebral
amyloid angiopathy, as well as neurofibrillary tangles
(NFT) composed of hyperphosphorylated tau. It is widely
accepted that mutations in the PSEN genes cause AD by
influencing AβPP processing to yield Aβ42 preferentially
[13]. Moreover the early age of clinical onset in FAD due
to PSEN mutations appears to correlate with an increase
in Aβ42 production and an associated decrease in Aβ40
genesis [14]. In addition, PSEN mutations appear to gen-
erate more Aβ42 than Aβ40 in transgenic mice and cul-
tured cells [15-22]. This increase in the Aβ42/40 ratio due
to PSEN mutations has been described as a 'gain of toxic
function' [23]. However, in a recent publication, several of
the PSEN mutations in transfected tissue culture cells
secreted more Aβ40 than Aβ42 [24]. In addition, most
PSEN mutations show reduced proteolytic activity on
AβPP and a variety of other substrates, a phenotype that is
recognized as a 'loss of function' [25]. Intriguingly, it has
recently been established that total loss of PSEN1 and
PSEN2 function in mice results in severe neurodegenera-
tion analogous to that observed in AD, but without amy-
loid pathology [26].
Hyperphosphorylated forms of the microtubule associ-
ated protein tau are the major component of NFT, repre-
senting one of the pathologic hallmarks of SAD and FAD.
Detailed chemical analyses of NFT has demonstrated sub-
stantial quantities of fatty acids, glycolipids and ganglio-
sides, which suggest a membrane associated origin [27-
30]. Electron microscopic studies have revealed that
paired helical filaments (PHF) are intimately associated
and probably derived from stacks of denatured cytomem-
branes such as smooth endoplasmic reticulum, Golgi and
mitochondria [31,32].
One of the multiple proteins that γ-secretase hydrolyzes is
Notch-1, a 2,532 amino acid transmembrane type-I pro-
tein (Swiss-Prot: P46531). In humans, the Notch family
contains four highly conserved molecules (Notch1-4).
Notch is a heterodimeric receptor involved in multiple
and complex signaling pathways that include neuronal
function and development, cardiovascular homeostasis,
angiogenesis and cell regeneration [33-35]. Notch dys-
function elicits a large number of developmental defects
and adult diseases such as different types of cancers [36].
Paralleling AβPP degradation, Notch-1 is cleaved at site S2
by the transmembrane ADAM/TACE proteases releasing
the extracellular N-terminal region of the molecule that is
bound to the Delta-type ligand on an opposing cell. Anal-
ogous to the AβPP γ/ε-sites, cleavage of Notch by the γ-
secretase at sites S3 and S4, close to the cytoplasmic face
of the membrane bi-layer, releases the Notch-1 Intracellu-
lar Domain (NICD). This 80 kDa C-terminal fragment is
translocated into the nucleus, where it activates the ubiq-
uitous transcription factor complex CBF1/Suppressor of
Hairless/Lag1 (CSL), to increase the expression of a large
number of genes [37-40].
Proteolytic degradation of N-cadherin, a molecule pro-
moting neuronal cell adhesion is also mediated by γ-secre-
tase. N-cadherin is an 881 amino acid type-I
transmembrane calcium dependent molecule (Swiss-Prot:
P19022) with five extracellular cadherin repeats and a
short highly conserved cytoplasmic tail that interacts with
the actin cytoskeleton through catenin molecules [41,42].
N-cadherin functions in cell-adhesion, embryogenesis,
differentiation, migration, invasion, signal transduction,
control of neuronal growth, synaptic configuration and
neural plasticity [43-45]. Cleavage of N-cadherin by
PSEN1 results in the generation of N-Cad/CTF2 which
forms a complex with the transcriptional co-activator fac-
tor CBP (CREB binding protein) to repress transcription.
It has been suggested that PSEN mutations lead toMolecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
Page 3 of 18
(page number not for citation purposes)
decreased N-Cad/CTF2 production, increased CBP/CREB
mediated transcription activity and FAD [46].
Another important substrate of the presenilins is Erb-B4,
a 1,283 amino acid type-I molecule (Swiss-Prot:
Q15303), and a component of the epidermal growth fac-
tor (EGF) receptor that forms part of the family of tyrosine
kinases [47]. Erb-B4 is involved in a wide range of cellular
functions such as mitogenesis, differentiation, growth
inhibition and survival [48]. Cleavage of Erb-B4 by tumor
necrosis factor converting enzyme generates an ~80 kDa
fragment that is subsequently hydrolyzed by γ-secretase to
yield the cytoplasmic domain (B4ICD) that functions as a
transcription factor [49-52]. In relation to AβPP metabo-
lism, recent data suggests that the endogenous AICD is
capable of binding to the promoter of the EGF receptor
genes [53]. Important in this cascade of events are the
neuroregulins (NRG), a group of neurotrophic factors that
control tissue development, neuronal survival, synap-
togenesis, microglial activation, astrocytic differentiation
and oligodendrocyte survival by activating Erb-B receptors
[54-56]. In SAD both NRG and Erb-B4 are associated with
neuritic plaques [54].
In the present study, we compared neuropathological and
biochemical findings among nine independent PSEN1
and one PSEN2 FAD cases, four SAD cases and two non-
demented (ND) controls. A morphological account is
given of the different types of Aβ plaques and NFT and
their relative abundances. We determined Aβ40 and Aβ42
peptide levels, and the processing pattern and relative
quantities of AβPP N-terminal and C-terminal peptides
and soluble tau. We also investigated the differences
among the PSEN mutations, as well as between the PSEN
group and SAD or ND controls, with respect to Notch-1,
N-cadherin and Erb-B4, molecules that are cleaved by the
γ-secretase complex. These differences may reflect the
effect of particular PSEN mutations on the multiple path-
ways in which the presenilins are involved. The significant
differences among PSEN mutations are probably due to
the position and the nature of PSEN amino acid substitu-
tions, and the impact these mutations have upon multiple
molecules involved in neuronal, glial and cerebrovascular
homeostasis.
Materials and methods
Human tissues and neuropathology
Brains were removed from ten individuals carrying the
following PSEN mutations; (PSEN1: A79V, A260V,
F105L, Y115C, A431E, V261F, V261I, M146L and P264L,
and PSEN2: N141I) and from four cases with SAD and
two ND individuals. The postmortem interval (PMI) aver-
ages for the PSEN1/2 mutations, SAD and ND control
subjects were 12.3 h, 10.8 h and 3.5 h, respectively. The
discrepancy in PMI between the ND controls and SAD/
PSEN patients is due to the different locations of tissue
procurement. The ND controls were obtained from the
Brain Bank at Sun Health Research Institute whose aver-
age PMI of 2.75 h is due partially to a rotating team that is
on call 24 hours a day and the deaths occurring in the
same community as the Institute [57]. Other centers, how-
ever, cannot shorten these times for multiple reasons. In
particular, the PSEN brains were obtained from different
laboratories that have different internal routines and time
standards and had to be shipped on dry ice to the Indiana
Alzheimer Disease Center. The average ages at death in the
three cohorts were 53 years for the PSEN, 64 years for the
SAD and 80 years for the ND group. The mean age at dis-
ease onset for the PSEN mutation subjects was 45 years
and 52 years for the SAD cases. An attempt was made to
use younger SAD individuals to make comparisons with
the PSEN subjects more relevant.
In the PSEN group, five individuals were female and five
were male. Three subjects were male and one individual
was female in the SAD cohort. In the case of the ND con-
trols, there was one male and one female. The left hemi-
sphere from each case was fixed in 10% formalin, while
the right hemisphere was frozen for genetic and biochem-
ical studies. Fixed cerebral hemispheres were cut into
coronal sections. For histological analyses, a sample of
superior frontal and cingulate gyri were obtained for each
case from sections at the level of the nucleus accumbens,
corresponding to the section of frozen tissue from the
contralateral hemisphere used for biochemical analysis.
The tissue was dehydrated in a graded alcohol series,
cleared in xylene and embedded in paraffin. Sections (8
μm) were processed according to the following methods:
Weigert, hematoxylin-eosin, Woelcke-Heidenhain,
Bodian and thioflavin-S. For immunohistochemical stud-
ies a panel of different antibodies was used. These
included monoclonal antibody 3D6 against Aβ1-5 (Elan
Corp., San Francisco, CA), monoclonal 10D5 against Aβ3-
6 (Elan Corp.), monoclonal antibody 6E10 against Aβ1-
14, monoclonal antibody 4G8 against Aβ16-24 (Signet
Laboratories, Dedham, MA) and monoclonal antibody
HYB310-01 against Aβ10-16 (Antibody Shop, Copenha-
gen, Denmark). Amyloid-β immunoreactive deposits in
the frontal cortex, were classified into distinct morpholog-
ical types as cotton-wool plaques (CWP), mature plaques,
primitive plaques and diffuse plaques, as previously
described [58,59]. Amyloid plaques and NFT were
counted over three randomly selected non-overlapping 1
mm2 microscopic fields.
Aβ ELISAs
Brain tissue gray matter was homogenized in a 10× vol-
ume of 90% glass distilled formic acid (GDFA) with an
electric grinder. The homogenates were centrifuged at
500,000 × g for 20 min at 4°C in a Beckman Optima TLA-Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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ultracentrifuge using a 120.2 rotor (Beckman, Fullerton,
CA). The supernatants were collected and dialyzed against
a solution of 5 M guanidine HCl, 50 mM Tris HCl, pH 8.0.
The samples were analyzed by ELISA using the anti-Aβ40
and anti-Aβ42 kits from Immunobiological Laboratories
(Minneapolis, MN) and from Innogenetics (Gent, Bel-
gium), respectively, and carried out following the manu-
facturer's instructions.
Western Blot Analysis
Brain tissue was homogenized in a 10× volume of RIPA
buffer (Sigma, St. Louis, MO; 150 mM NaCl, 1.0% IGE-
PAL® CA-630, 0.5% sodium deoxycolate, 0.1% SDS 50
mM Tris, pH 8.0), containing a protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany) at 4°C. The
homogenates were centrifuged at 14,000 × g for 20 min at
4°C in a Beckman Microfuge 22R centrifuge. The superna-
tants were collected and total protein quantified with a
BCA protein assay kit (Pierce, Rockford, IL). The samples
were placed in NuPage 2× LDS sample buffer (Invitrogen,
Carlsbad, CA) that contained 50 mM dithiothreitol and
heated at 80°C for 10 min. The proteins were electro-
phoresed on 4–12% Bis-Tris gels with NuPage 2-mor-
pholinoethanesulfonic acid (MES) as the running buffer
(Invitrogen). The proteins were then transferred onto 0.45
μm pore nitrocellulose membranes (Invitrogen) with
NuPage transfer buffer (Invitrogen) and 20% methanol.
The membranes were blocked with 5% non-fat milk in
phosphate-buffered saline (PBS), 0.5% Tween 20 (Fluka,
St. Louis, MO). Table 1 describes the primary and second-
ary antibodies used in the experiments. The proteins were
visualized with SuperSignal WestPico Chemiluminescent
(Pierce) substrate, CL-Xpose film (Pierce) and Kodak GBX
developer (Sigma). The films were scanned and analyzed
with a GS-800 calibrated densitometer (Bio-Rad, Her-
cules, CA) and Quantity One software (Bio-Rad). Anti-
bodies were removed from the membranes with Restore™
Western Blot Stripping Buffer (Pierce). The blots were
washed in PBS then blocked with 5% non-fat milk in PBS,
0.5% Tween 20 (Fluka, St. Louis, MO). Anti-mouse or
anti-rabbit actin antibody was used to re-probe the mem-
branes as protein normalization standards following the
techniques described above. All values in the histograms
have been corrected against actin abundance in all WB
densities shown in this study.
Apolipoprotein E Genotyping
DNA for apolipoprotein E (APOE) genotyping was
extracted from pieces of cerebral cortex [60]. Tissue (50
mg) was digested to completion with proteinase K (1 mg/
ml) at 55°C and purified using Wizard Genomic DNA
purification kit (Promega, Madison WI). For each PCR
reaction, approximately 500 ng of DNA from each sample
was used. PCR primers and amplification conditions
employed, and identification of APOE genotypes by HhaI
restriction enzyme digestion of amplified material, were
carried out according to published protocol [61]. To iden-
tify APOEε alleles, digested fragments were separated by
electrophoresis through 9% acrylamide gels and revealed
on ethidium bromide stained gels.
Results
I. Neuropathological findings and characterization of 
soluble Aβ and tau
A description of the most relevant demographic data and
neuropathological features of the cases examined in the
present study is shown in Table 2. In the PSEN mutation
and SAD cases, neuronal loss and gliosis range from mild
to severe. The two ND control individuals (81 year old
female and 79 year old man), had no apparent gross brain
atrophy and a sparse number of amyloid plaques with a
low number of NFT and Braak scores of I (range I-VI). The
individuals with PSEN mutations and SAD had an average
brain weight of 1,042 g and 1,143 g, respectively, while
the mean weight of the ND brains was 1180 g. In the
PSEN mutation group, the APOE allele frequencies were
ε2 = 0.10, ε3 = 0.80 and ε4= 0.10, while in the SAD group
they were ε2 = 0, ε3 = 0.62 and ε4 = 0.38 (Table 2). The
two ND individuals had ε2/ε3 and ε3/ε3 APOE genotypes.
A quantitative comparison of the different type and
number of neuropathological findings in the cerebral cor-
Table 1: Primary and Secondary Antibodies Used in Western Blots
Primary Antibody Antigen Specificity Secondary Antibody Company/Catalog #
22C11 AβPP aa. 66–81 M Millipore/MAB348
CT9APP Last 9 aa. of AβPP R Millipore/AB5352
Notch-1 NICD N-terminal 14 aa. R Millipore/AB5709
Erb-B4 C-terminal aa. 1258–1308 R Santa Cruz/sc-283
N-Cadherin aa. 802–819 M BD Transduction Laboratories/610920
Tau aa. 159–163 M Pierce/MN1000
Actin Ab-5 Clone C4 M BD Transduction Laboratories/A65020
Actin N-terminus of human γ-actin R Abcam/Ab37063
AβPP = amyloid-β precursor protein; aa. = amino acid sequence; NICD = Notch-1 intracellular domain; M = goat-anti mouse IgG, HRP conjugated 
(Pierce); R = goat-anti rabbit IgG, HRP conjugated (Pierce)M
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Table 2: Patient Information and Neuropathology Data
Case Gender Age at 
onset 
(yrs)
Age at 
death 
(yrs)
APOE 
Genotype
Brain 
Weight 
(g)
Frontal 
Atrophy
Neuronal 
Loss
Gliosis CAA *Avg 
CWP
*Avg 
Mature 
Plaques
*Avg 
Primitive 
Plaques
*Avg 
Diffuse 
Plaques
*Avg 
NFT
A79V-PSEN1 F 50 61 3/4 1060 2 2 2 0 0.00 8.67 43.67 65.33 9.00
A260V-PSEN1 M 40 46 2/3 1140 3 1/2 1/2 1 0.00 2.33 0.67 109.00 31.00
F105L-PSEN1 F 60 68 2/3 1070 2 2 2 1 0.00 1.00 0.00 78.67 17.00
Y115C-PSEN1 M 41 51 3/3 1026 2/3 2/3 2/3 1 0.00 0.67 8.67 70.67 31.33
A431E-PSEN1 F 35 43 3/3 764 PF 3 2/3 2/3 2 46.33 11.67 5.00 42.00 55.33
V261F-PSEN1 M 36 47 3/3 950 2 2 1 3 36.33 0.67 0.00 2.00 49.00
N141I-PSEN2 M 42 57 3/4 1136 2 1/2 1/2 2 0.00 2.00 1.33 67.67 65.00
V261I-PSEN1 F 48 55 3/3 1185 1 2 2 2 49.00 1.00 0.00 1.67 0.00
M146L-PSEN1 M 47 52 3/3 1150 1 2 2 1 0.00 14.00 0.00 102.00 14.33
P264L-PSEN1 F 48 53 3/3 940 2 2 2 0 13.67 8.00 0.00 12.67 14.67
sporadic AD M 47 62 3/3 910 2 2/3 2/3 1 0.00 23.33 0.00 12.00 42.33
sporadic AD M 55 66 3/4 1325 1 2/3 2/3 1 0.00 11.67 0.00 30.67 6.33
sporadic AD M 58 73 3/4 1236 PF 2 2 2 2 0.00 5.67 0.00 15.33 12.00
sporadic AD F 48 55 3/4 1100 3 2/3 2/3 0 0.00 36.67 0.00 21.33 55.33
*all counts are measured in mm2; yrs = years; APOE = apolipoprotein E; g = grams; CAA = cerebral amyloid angiopathy; avg = average; CWP = cotton wool plaques; NFT = neurofibrillary tangles; F = female; 
M = males; yrs = years; AD = Alzheimer's disease; PSEN = presenilin; PF = post-fixed; 0 = none; 1 = mild; 2 = moderate; 3 = severe;Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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tex of the PSEN mutation cases and the SAD cases is given
in Table 2. A representative display of their morphology is
shown in Figure 1. Cotton-wool plaques (CWP) were the
most abundant type of Aβ deposit in four cases of PSEN1
mutations: A431E, V261F, V261I and P264L. They were
observed throughout the cortical layers, although they
were more abundant in the upper layers. The diameter of
these plaques varied from an average of 80–90 μm in
A431E, V261F and P264L cases to 145 μm in the V261I
case. Their mean frequency was approximately 40–50
plaques/mm2 in the A431E, V261F and V261I mutations.
The P264L mutation case displayed a reduced number of
CWP (average of 14/mm2), consistent with its overall
reduced burden of Aβ deposition compared to that of the
remaining cases. No CWP were observed in the superior
frontal and cingulate gyri in the SAD group and in the
cases with the PSEN1 mutations: A79V, A260V, F105L,
Y115C and M146L and the PSEN2 N141I mutation.
Diffuse plaques, mostly prevalent in the intermediate cor-
tical layers, constituted a common type of Aβ deposit.
Their abundance varied substantially among the different
mutations. They were most numerous in the A260V muta-
tion (mean 109 plaques/mm2) and M146L mutation
(102 plaques/mm2), but sparse in cases with V261F or
V261I mutation (~2 plaques/mm2). Diffuse plaques were
the predominant type of Aβ deposit in the PSEN1 muta-
tions A79V, A260V, F105L, Y115C and M146L and the
PSEN2 N141I mutation. The P264L mutation case dis-
played a similar number of CWP and diffuse plaques. The
SAD group had an average of 19.8 plaques/mm2 diffuse
plaques (range 12.00–30.67).
Mature cored neuritic plaques were observed throughout
all cortical layers, but were more frequent in the lower cor-
tical layers. Their frequency varied among the different
mutations, being higher in A431E and M146L PSEN1
mutations, and lower in the remaining cases. Neuritic
plaques were less prevalent than CWP and diffuse
plaques, and correlated approximately with the overall
burden of Aβ deposition. They were only rarely observed
in the cases with V261F or V261I mutation. In general,
primitive plaques were abundant only in the PSEN1 A79V
mutation with a few also seen in the upper cortical layers
of Y115C and A431E PSEN1 mutations. Primitive plaques
were not seen in the SAD cohort, while the mature
plaques averaged 19.3 plaques/mm2 (range 5.67–36.67/
mm2).
The number of NFT grossly correlated with the overall
burden of Aβ deposition. Nine of the PSEN cases dis-
played moderate to severe degrees of neurofibrillary
degeneration (mean NFT value = 31.8/mm2; range 14.3 to
65/mm2), with the exception of the V261I mutation, in
which sparse NFT were observed. Similar values were
observed in the SAD cases (mean NFT value = 29.0/mm2;
range 6.3 to 55.3/mm2). A negative slope correlation was
observed between the number of NFT and disease dura-
tion (R = 0.70).
Quantification of Aβ levels in the cerebral cortex revealed
that in four out of ten PSEN mutations Aβ40 was present
in higher amounts than Aβ42 (Table 3 and Figure 2).
Presenilin-1 cases with the A431E, V261F, V261I and
M146L mutations had Aβ42/Aβ40 ratios of less than 1.00,
being more prominent in the former two than in the latter
two cases (0.28 and 0.18 versus 0.43 and 0.68). In one
case (F105L), the ratio was close to 1:1 (Table 3). A similar
pattern was found in two out of four SAD cases (Aβ42/
Aβ40 ratios of 0.61 and 0.90). Cortical vascular amyloid
in the four PSEN mutation cases cited above had scores of
2, 3, 2 and 1 (Table 2), where the scores 1, 2 and 3 corre-
spond to mild, moderate and severe vascular amyloid
deposits, respectively. In addition, three out of these four
PSEN cases also had the highest values of CWP with the
remaining individual (M146L) having a high number of
diffuse deposits (102 per mm2) and mature plaques
(14.00 per mm2) (Table 2). With the exception of PSEN
cases A79V and P264L, in which very mild cortical vascu-
lar amyloid was evident in histological sections, all PSEN
cases had mild to moderate amyloid angiopathy in the
gray matter. Severe cortical amyloid angiopathy was only
seen in the case of V261F. However, examination of iso-
lated leptomeningeal vessels from all PSEN mutation
cases demonstrated extensive vascular amyloidosis, as
shown in Figure 3, which ranged from moderate (two
cases) to moderate/severe (one case) to severe (five cases).
In agreement with the cortical vascular amyloid assess-
ment, cases A79V and P264L had negligible amounts of
leptomeningeal vascular amyloid (data not shown). The
amount of cortical vascular amyloid in the SAD cases
ranged from none to moderate. The two ND cases had a
mild form of CAA. In addition, we found that within the
PSEN cohort positive correlation existed between levels of
brain Aβ40 and degree of vascular amyloidosis (R = 0.81).
Overall, the neuropathological distribution of the differ-
ent types of plaques, the intensity of cerebrovascular amy-
loid and the number of NFT substantially differed among
the nine PSEN1 and one PSEN2 mutations as well as from
the four SAD cases used as pathology comparison con-
trols. A detailed account of these parameters is given in
Table 2 and Figures 1 and 3.
Tau antibody probing revealed a series of bands with a
range of ~110 to ~28 kDa (Figure 4), representing both
normal and PHF-tau [62]. In seven out of ten PSEN muta-
tions there were bands that corresponded to dimeric
forms of tau (~100–110 kDa). In general, the PSEN muta-
tions demonstrated elevated amounts of soluble tau pro-Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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Figure 1 (see legend on next page)Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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tein relative to the ND controls, the exception being the
~28 and ~57 kDa bands (Figure 4). The PSEN A79V and
V261I mutations revealed low NFT counts on neu-
ropathological examination (Table 2), and on WB had rel-
atively moderate amounts of soluble tau peptides and
were missing the ~100–110 kDa (dimeric) peptides (Fig-
ure 4). The case with the A260V mutation, which also was
missing the ~100–110 kDa peptides, had an average
amount NFT (31.00 per mm2) (Table 2). The PSEN cases
with the highest NFT scores (A431E, V261F, and N141I;
Table 2) also had the highest levels of dimeric tau as
observed by WB (Figure 4).
II. Characterization of AβPP, Notch, N-cadherin, Erb-B4 
Processing
The N- and C-terminal peptide degradation of AβPP was
investigated by WB (Figure 5). The total amount of AβPP
(~110 kDa), detected by the 22C11 antibody appears to
be approximately increased two-fold among the PSEN
mutations compared to ND controls. The total AβPP in
SAD cases was the same or slightly elevated than those
observed for ND controls (Figure 5A). The 28 and 25 kDa
peptide bands were faint in ND cases and significantly ele-
vated in the PSEN mutations in general, suggesting a
larger accumulation of N-terminal peptides. A variable
amount of N-terminal peptides were observed in SAD
cases in relation to those of ND controls. The C-terminal
(CT) peptides detected by the CT9APP antibody demon-
strated a greater accumulation of the CT99/CT83 bands in
PSEN mutations and SAD cases than those observed in
ND controls. In contrast, SAD cases showed elevated
quantities of CT peptides than those observed in both the
ND and PSEN cohorts (Figure 5B). The levels of AβPP
were increased compared to CT peptide levels in ND con-
trols and PSEN cases. This ratio was inversed in the SAD
group (Figure 5B). Intriguingly, there was a ~40 kDa band
that our laboratory has routinely observed in other FAD,
SAD, ND controls and transgenic mice which we are pres-
ently investigating.
Analysis of Notch-1 by WB suggested that the S3 cleavage
was negligible in seven of the ten PSEN mutations, since
the levels of the ~80 kDa NICD were very low. However,
we cannot exclude the possibility of a faster turnover of
the fragment resulting in lower steady-state levels. Two of
the remaining three cases (P264L and N141I), exhibited
lesser amounts of the 80 kDa NICD when compared to
ND controls, while the remaining case (Y115C) had com-
parable values to ND controls (Figure 6A). The detected
amounts of the NICD peptide in SAD were very heteroge-
neous. In one case only trace amounts of NICD were
present. In two cases this peptide existed at lower levels
Histology and immunocytochemistry of amyloid deposits in PSEN mutations Figure 1 (see previous page)
Histology and immunocytochemistry of amyloid deposits in PSEN mutations. A) PSEN2 N141I mutation primitive 
plaques immunoreacted with 10D5 antibody. B) Cotton wool plaques in the PSEN1 A431E mutation immunoreacted with the 
21F12. On the upper-right corner there is a mature plaque. C) Cotton wool plaques associated with the PSEN1 A260V muta-
tion immunoreacted with the 10D5 antibody. D) Mature neuritic plaque observed in the PSEN1 A79V mutation. 10D5 anti-
body. E) Primitive plaque localized the cerebral cortex of the PSEN1 A79V mutation immunoreacted with the 10D5 antibody. 
F) Cortical amyloid plaques immunoreacted with the 10D5 antibodies at low magnification in the PSEN1 V261F mutation. 
Numerous CWP and occasional mature core neuritic plaques are observed in addition to severe amyloid angiopathy. G) Cot-
ton wool plaques in the PSEN1 V261F mutation developed with the 10D5 antibody. H) Abundant CWP observed in the PSEN1 
V261F stained by hematoxilin and eosin. The plaques are surrounded by a discreet number of reactive astrocytes. In the 
remaining areas of the field several regions of severe neuronal loss and glyosis and moderate microvacuolization are observed. 
I) Severe Aβ immunoreactive cerebral amyloid angiopathy in the cerebral cortex of PSEN1 A431E mutation. J) A hematoxylin 
and eosin stained section of the cerebral cortex of PS1 431E mutation. Magnifications: 63 × (A, B, C, D, E, G); 40 × (I and J); 20 
× (H) and 10 × (F). Scale Bars = 20 μm.
Histogram depicting the relative amounts of Aβ40 and Aβ42  detected by ELISA Figure 2
Histogram depicting the relative amounts of Aβ40 
and Aβ42 detected by ELISA. Notice the abundant 
amount of Aβ40 in the PSEN A431E, V261F, V261I and 
M146L. The amounts of Aβ40 and Aβ42 were almost equiva-
lent in case F105L. PSEN = presenilin; SAD = Alzheimer's dis-
ease; ND = non-demented.Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
Page 9 of 18
(page number not for citation purposes)
than those in ND controls while in one individual the
level was higher than the ND controls (Figure 6A).
Our WB data demonstrated both full-length N-cadherin
(110 kDa) and the CT fragment (28 kDa), as observed in
other laboratories [46,63,64]. The level of full-length N-
cadherin was decreased in all PSEN mutation carriers as
well as in SAD cases when compared to ND controls (Fig-
ure 6B). With the exception of two PSEN1 mutations
(A260V and M146L), the remaining PSEN mutations and
two ND controls showed variable amounts of the ~28 kDa
peptide. This pattern was also observed in the SAD cohort
(Figure 6B).
The total levels of Erb-B4 (~180 kDa) were reduced in the
PSEN mutations, relative to ND cases as revealed by WB.
A similar pattern was observed in the SAD cohort (Figure
7). In PSEN and SAD individuals there was a reduction of
the ~60 kDa peptide. The most prominent band (~55
kDa) showed variable quantities among the PSEN muta-
tions and ND controls. Cases F105L and P264L had the
highest amounts of the ~50 kDa band with the remaining
PSEN cases and ND controls having similar quantities. In
most of the PSEN mutations the ~40 kDa band was 2–10
fold diminished, while the ~30 kDa peptide had heteroge-
neous values (Figure 7). Absorption experiments by our-
selves (data not shown) and others [65,66], revealed that
the fragments were specific to Erb-B4. Overall, the WB pat-
terns suggest that in the PSEN mutations, Erb-B4 has a
high degree of variation in CT peptide degradation (Figure
7).
Discussion
One of the most significant characteristics of the ten stud-
ied PSEN mutations was their early age of clinical onset
(mean: 44.7 years, range 35–60), which confirms previ-
ous observations (reviewed in reference [67]). Younger
SAD individuals (mean: 64 years, range 55–73) were used
in the study in order to make the comparisons more
equivalent. The different PSEN mutations exhibited sub-
stantial heterogeneity in duration of the disease, degree of
brain atrophy, neuronal loss, cortical and leptomeningeal
vascular amyloidosis and basic type, number and distri-
bution of amyloid plaques. Likewise, the NFT demon-
strated a wide range of variation in amount and
distribution among the ten PSEN mutation individuals.
These sharply different pathological manifestations sug-
gest that a single genetic change in the PSEN genes results
in the phenotypic variations associated with each distinct
PSEN mutations due to complex pleiotropic effects.
It is widely accepted that a major pathological effect of
PSEN mutations is a proportionately larger production of
toxic Aβ42 [15-22]. In our study, this hypothesis was sup-
ported by the high Aβ42/Aβ40 ratio observed in six PSEN
mutation cases. However, in four instances PSEN muta-
tions resulted in Aβ40 levels that were substantially higher
than those of Aβ42. In terms of mean ng/g of cerebral cor-
tex, the PSEN mutations had significantly more Aβ40
(7,093) than Aβ42 (4,856), while the SAD cases had less
Aβ40 (2,627) than Aβ42 (3,322) and the ND cases had
very small amounts of both Aβ40 (42) and Aβ42 (132).
These differences may, in part, be due to a larger amount
of cerebrovascular amyloidosis in which Aβ40 deposits
Thioflavin-S histochemistry of leptomeningeal vessels Figure 3
Thioflavin-S histochemistry of leptomeningeal ves-
sels. Whole mounts of leptomeningeal vessels stained by 
thioflavine-S demonstrating amyloid angiopathy among the 
different PSEN mutations. A) PSEN1 M146L: moderate; B) 
PSEN1 V261I: severe; C) PSEN2 N141I: severe. D) PSEN1 
V261F: severe; E) PSEN1 A431E: severe; F) PSEN1 Y115C: 
moderate; G) PSEN1 F105L: severe and H) PSEN1 A260V: 
moderate-severe. The remaining two PSEN1 mutations 
A79V and P264L had a mild amyloid deposition (data not 
shown). Scale Bars = 500 μm.Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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predominate. However, previous PSEN studies in which
the ratio of Aβ42/Aβ40 was elevated were mostly per-
formed in either cell cultures or in mice expressing
mutated PSEN genes [23]. Vascular amyloidosis plays a
fundamental pathological role in PSEN dementias and in
FAD and SAD by altering blood-brain barrier permeability
and obstructing the small cerebral vessels. In larger arter-
ies it obliterates the tunica media with loss of compliance,
thus decreasing brain perfusion. Furthermore, severe
perivascular amyloid deposition blocks the periarterial
spaces that remove the interstitial fluid of the brain into
the systemic circulation, resulting in dilation of the peri-
arterial spaces, brain edema and grave hemodynamic
alterations [68,69]. Isolated leptomeninges from PSEN
mutation cases also displayed a wide variation in amyloid
angiopathy.
We observed no elevation in the frequency of APOE ε4
allele as it occurs in SAD, suggesting that this allele may
not play a pivotal role in the PSEN phenotype. However,
a larger population of PSEN mutations will need to be
studied to endorse such a conclusion. Interestingly, in the
PSEN1 mutation group, those two individuals that carried
the APOE ε2/ε3 genotype (A260V and F105L mutations)
had the lowest amount of total Aβ in the frontal cortex,
averaging 1,533 ng/g of tissue. By contrast, the remaining
PSEN mutation subjects had an average total Aβ of 14,554
ng/g of tissue, a 9-fold greater level. These sharp differ-
ences suggest that the presence of APOE ε2 allele may play
a role in limiting Aβ production and/or its accumulation.
Total levels of soluble tau protein were increased in many
PSEN mutation cases compared to ND controls. Interest-
ingly, seven out of the ten PSEN mutations exhibited
dimeric tau levels as did three out of four SAD cases. None
of the control cases showed dimeric tau. Additionally, two
out of three PSEN cases that did not have the dimeric tau
bands, had the two lowest NFT neuropathology counts.
The remaining case had an average amount of NFT. The
cases that had the three highest NFT counts also had the
highest dimeric tau values as observed by WB. These find-
ings can be explained by the fact that dimerization of tau
is pivotal in nucleation and in paired filament elongation
[70]. Given that NFT are an important hallmark of AD,
since they obliterate neurons and their neuritic arbors and
are in part responsible for the dementing process in PSEN
mutations, it is surprising to find a wide degree of hetero-
geneity in soluble tau levels and insoluble NFT pathology.
Based on previous studies, abnormal phosphorylation of
soluble tau apparently results in filament formation, sug-
gesting that phosphorylation may be a driving force in
NFT assembly [71,72].
Table 3: Aβ ELISA Values
Case Aβ40 ng/g wet weight Aβ42 ng/g wet weight total Aβ ng/g wet weight ratio Aβ42/Aβ40
A79V-PSEN1 1039.59 6653.02 7692.60 6.40
A260V-PSEN1 442.61 1550.19 1992.81 3.50
F105L-PSEN1 497.31 575.18 1072.49 1.16
Y115C-PSEN1 531.35 5936.06 6467.41 11.17
A431E-PSEN1 27015.06 7530.96 34546.02 0.28
V261F-PSEN1 21373.91 3858.75 25232.66 0.18
N141I-PSEN2 1530.44 6734.30 8264.74 4.40
V261I-PSEN1 7736.66 3326.98 11063.64 0.43
M146L-PSEN1 8312.70 5680.64 13993.34 0.68
P264L-PSEN1 2452.49 6716.37 9168.86 2.74
Average 7093.21 4856.25 11949.46 3.09
SD 9560.57 2399.22 10429.32 3.52
sporadic AD 3815.67 2310.17 6125.84 0.61
sporadic AD 4235.19 3811.51 8046.71 0.90
sporadic AD 1524.04 2884.46 4408.50 1.89
sporadic AD 931.20 4280.58 5211.78 4.60
Average 2626.53 3321.68 5948.21 2.00
SD 1642.32 889.52 1565.06 1.82
ND control 40.73 148.30 189.03 3.64
ND control 42.52 114.79 157.31 2.70
Average 41.62 131.55 173.17 3.17
SD 1.27 23.69 22.43 0.67
PSEN = presenilin; SD = standard deviation; AD = Alzheimer's disease; ND = non-dementedMolecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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Western blots of soluble tau isoforms quantified by scanning densitometry Figure 4
Western blots of soluble tau isoforms quantified by scanning densitometry. The overall quantities of soluble tau iso-
forms substantially varied among the different PSEN mutations and SAD cases and from the ND controls. Most of the tau pro-
teins were concentrated between ~60–40 kDa. In general there was more tau protein in the PSEN mutations than in the ND 
controls. There were prominent bands at ~100–110 kDa in 7 out of 10 PS mutations that were absent in the ND controls. 
Likewise, this band was seen in 3 out of 4 of the SAD cases and not in the ND controls. These bands may correspond to 
dimeric forms of tau. SAD = sporadic Alzheimer's disease; ND = non-demented.Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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Western blots of AβPP and N- and C-terminal related peptides Figure 5
Western blots of AβPP and N- and C-terminal related peptides. A) The amounts of AβPP holoprotein (110 kDa) and 
28 and 25 kDa bands are increased in all PSEN mutations relative to the ND controls. The 110 kDa (AβPP) in SAD is almost 
equivalent to the ND cases, but is variable with respect to the 28 and 25 kDa bands. B) In our SDS-PAGE system the CT99 and 
CT83 co-migrate as a single band at ~14 kDa. As can be appreciated, the ND controls have significantly less CT peptides than 
the PSEN and SAD cases. In addition, AβPP (110 kDa) was variable between the PSEN cases and the ND controls, but was 
decreased in the SAD cases compared to the ND controls. SAD = sporadic Alzheimer's disease; ND = non-demented.Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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Western blots of the 80 kDa Notch-1 intracellular domain (NICD) and N-cadherin/CTF2 Figure 6
Western blots of the 80 kDa Notch-1 intracellular domain (NICD) and N-cadherin/CTF2.A) Notice that, with the 
exception of 3 PSEN mutation cases (Y115C/PSEN1, N141I/PSEN2 and P264L/PSEN1), all the PSEN mutations have reduced 
quantities of NICD transcription factor. In the SAD cases, there is a heterogeneous distribution of NICD, being almost negligi-
ble in one SAD case, elevated in a second case and diminished in the remaining two, relative to the ND controls. B) The 
amount of N-Cadherin holoprotein detected at 110 kDa is reduced in all PSEN cases relative to the ND controls. A similar 
pattern is observed for the SAD cases. The N-Cad/CTF2 band at 28 kDa is decreased in all PSEN mutations with the exception 
of A260V and M146L mutations that displayed higher values. The quantities of the N-Cad/CTF2 were variable in the SAD rela-
tive to the ND levels. SAD = sporadic Alzheimer's disease; ND = non-demented.Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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Western blots of Erb-B4 Figure 7
Western blots of Erb-B4. Overall, the bands corresponding to the holoprotein (~180 kDa) and ~60 kDa were decreased in 
all PSEN mutations as well as in the SAD cases relative to the ND controls. Of the degradation peptides that carry the Erb-B4 
C-terminal epitope the most represented band, at ~55 kDa, demonstrated heterogeneous levels among different PSEN muta-
tions. In the SAD cases the values were more similar to the control levels. The ~50 and ~30 kDa peptide bands also show large 
deviations among the PSEN, SAD and ND controls. The ~40 kDa band was increased in the ND controls when compared to 
the PSEN and SAD cases. SAD = sporadic Alzheimer's disease; ND = non-demented.Molecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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There was an interesting contrast between the amount of
AβPP and CT peptides in the PSEN mutations as the oppo-
site situation was shown for the SAD cases, where the
amount of CT peptides was by far elevated relative to the
AβPP. The reversed ratios imply an accumulation of AβPP
in most of the PSEN mutations, probably due to defective
γ-secretase that limits the generation of Aβ and AICD. Par-
adoxically, in SAD cases, the presence of abundant CT
peptides, suggests a very active β-secretase with an accu-
mulation of CT fragments relative to ND control levels.
The elevation of CT peptides in PSEN and SAD cases com-
pared to ND controls is also of interest because one would
expect these fragments to be diminished, or at least to be
found at the levels of the ND cases, in view of the univer-
sal accumulation of Aβ in the SAD individuals. An
increase in CT fragments may be a toxic factor in PSEN
dementias and SAD as happens in animal models. In
transgenic mice expressing the CT100 amino acid domain
of AβPP, there are neuronal and synaptic pathologies,
intracellular accumulation of CT fragments, hippocampal
degeneration, cerebrovascular alterations and cognitive
deficits [73-76]. The accumulation of Aβ in PSEN and
SAD individuals is probably due to decreased enzymatic
degradation and decreased clearance of these molecules
into the systemic circulation. It has recently been sug-
gested that a single PSEN-affected gene may act as a dom-
inant-negative mutant capable of inhibiting the normal
activity of other molecules, such as cAMP-response ele-
ment (CRE)-dependent gene expression, as well as NMDA
receptor function and synaptic plasticity leading to cell
death [77]. It is also possible that structural changes
resulting from PSEN mutations may generate longer than
Aβ42 peptides that remain membrane bound and have a
toxic cumulative effect [78]. In addition, PSEN mutations
may increase the accumulation of AβCT terminal peptides
[79]. There are two possible mechanisms for the observed
accumulation of AβPP in the PSEN mutations. First, the
increased levels may be due to a failure of the mutated
PSEN to cleave AβPP and yield Aβ peptides. Second, it has
been suggested that PSEN1 is also a regulator of β-secre-
tase [80] and therefore its dysfunction could result in the
accumulation of AβPP.
Mutations in the PSEN genes result in a complicated plei-
otropic cascade since they generate a large number of
aberrantly processed molecules and factors that pro-
foundly alter brain function and manifest in an early dis-
ease onset, a wide range of clinical symptoms and diverse
final neuropathology. Important in this pathology are the
peptides derived from γ-secretase hydrolysis that are
essential in structural and regulatory functions such as
those produced by AβPP, Notch-1, N-Cadherin and Erb-
B4. Notch processing appeared to be impaired in all ten
PSEN cases compared to ND cases, but in seven cases this
effect was profound with an almost complete absence of
detectable NICD. A direct role for PSEN mutations in the
apparent reduction of NICD expression has yet to be
established. However, given the large number of genes
that are activated by the NICD/CSL transcription factor,
important pathophysiological changes occur that may
play a large role in the development of these dementias.
In contrast to ND cases, all PSEN mutations and SAD indi-
viduals demonstrated a reduced amount of N-Cadherin,
which in part may be due to either mutations in PSEN
genes or to limited function of γ-secretase. Aberrant
processing of N-Cadherin would trigger the accumulation
of CBP resulting in damage to CREB transcriptional func-
tion and in impaired synaptic transmission and synaptic
morphogenesis and ensuing cognitive decline [81,82].
Erb-B4 and B4ICD domain levels were lower in all PSEN
and SAD cases in comparison to ND controls. Synthesis of
both peptides may be limited by mutations in γ-secretase,
as it occurs with the inhibition of γ-secretase in tissue cul-
ture cells that results in the accumulation of CT fragments
[52]. Defective processing of Erb-B4 by γ-secretase may
cause deviant endoproteolysis, thus explaining the multi-
ple Erb-B4 CT related peptides observed in our WB. It has
been suggested that a defective balance between AβPP an
Erb-B4 hydrolysis may contribute to neurodegeneration,
memory deficits and synaptic dysfunction without gener-
ating amyloid plaques [83]. In addition, a decrease in Erb-
B4 leads to the up-regulation of GFAP that may enhance
the astrocytosis observed in SAD [84].
Conclusion
The early onset and morphological and biochemical
diversity observed among the PSEN mutations are obvi-
ously related to the particular site and type of mutation.
The fact that SAD and PSEN mutations both accumulate
Aβ, suggest that AβPP and Aβ peptides play an important
role in brain aging. Furthermore, AβPP mutations in the
inherited forms of FAD that flank or lie within the Aβ
sequence, underscore the potential metabolic importance
of the CT99 and Aβ peptides. This suggests that Aβ may
represent a rescue molecule in different neurodegenera-
tive pathologies [85]. Therapeutic interventions, such as
Aβ immunization as a prophylactic AD venue, should be
administered to younger clinically healthy carriers of
PSEN mutation families, to assess the effects of preventing
Aβ deposition and to clinically evaluate to which extent
Aβ is responsible for the dementia observed in AD.
Presenilin mutations, although inducing an early-onset
dementia with overall similarity to SAD, exhibit a range of
pathologic and clinical phenotypes. This complexity
belies the simple explanatory hypothesis that suggests a
straightforward preferential production of Aβ42 as a sole
underlying biochemical mechanism. Systematic examina-
tion of 10 PSEN mutation cases revealed that only half
exhibited substantially increased Aβ42:Aβ40 ratios. ThisMolecular Neurodegeneration 2008, 3:20 http://www.molecularneurodegeneration.com/content/3/1/20
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suggests that neither increased production nor enhanced
accumulation of Aβ42 accounts for the range of patholog-
ical effects resulting from a large number of altered PSEN
functions. In view of these differences, the multiple sub-
strates affected, early age of onset and clinical course and
the presentation of a different therapeutic target, FAD due
to PSEN mutations may be better classified as "Presenilin
Dementias," with the caveat that more information is
needed to justify their departure from FAD.
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